Baxter Healthcare to Sell New Blood-Clotting Drug
- Share via
Baxter Healthcare Corp.’s Glendale-based Hyland division said it will begin U.S. distribution of a drug made by Kabi Vitrum AB, a Swedish pharmaceutical company, for patients with antithrombin III deficiency, a hereditary disorder that impairs proper blood clotting.
The drug, ATnativ, received approval from the U.S. Food and Drug Administration last December for marketing as an orphan drug, the term used for treatments for diseases with a patient population of 200,000 or less. ATnativ has been available in several European countries for clinical trials since the mid-1970s.
Baxter Healthcare is a unit of Baxter International, a major health-care products and services concern based in Deerfield, Ill.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
